Predictors and Impact of Timing of Disease Progression Following Primary Therapy in Multiple Myeloma

In conclusion, the duration of the PFS significantly influences survival, regardless of HR cytogenetic features. Therefore, it should be considered an important parameter for risk stratification in patients experiencing a relapse.PMID:38135634 | DOI:10.1016/j.clml.2023.11.008

Source: Clinical Lymphoma and Myeloma - December 22, 2023 Category: Cancer & Oncology Authors: Sarah Goldman-Mazur Alissa Visram S Vincent Rajkumar Prashant Kapoor Angela Dispenzieri Martha Q Lacy Morie A Gertz Francis K Buadi Suzanne R Hayman David Dingli Taxiarchis Kourelis Wilson Gonsalves Rahma Warsame Eli Muchtar Nelson Leung Robert A Kyle Sha Source Type: research